Tags
- 2024
- 27A
- Adverse
- Agonist
- Annual report
- Anthony Moore
- Antiviral drug
- Arbutus Biopharma
- Assembly
- Biosciences
- Biotechnology
- Blinded experiment
- Business operations
- CccDNA
- CFBV
- Chief business development officer
- Chief executive
- Chief executive officer
- Chief financial officer
- Chief operating officer
- Clinical
- Clinical trial
- Clinical Trials
- Commercialization
- Comparable
- Compound
- COVID-19
- Cure
- Data-driven
- Disease
- Drug
- Drug development
- Efficacy
- Employment
- Entry inhibitor
- Evaluation
- Executive
- Executive officer
- Factor
- Finance
- Form 10-K
- Form 10-Q
- Form 8-K
- From Time
- GlobeNewswire
- HBV
- HDV
- Health
- Hepatitis
- Hepatitis B
- Hepatitis B virus
- Herpes B virus
- Highlights
- Impaction
- Infection
- Innovation
- Interferon
- Interferon-alpha/beta receptor
- Interferon type I
- Jason Okazaki
- John Mchutchison
- Legal clinic
- Luisa Stamm
- Manufacturing
- MD–PhD
- Medical
- Michael Samar
- Michele Anderson
- News agency
- Officer
- Okazaki
- Open-label trial
- Pharmacokinetics
- PHASE 2
- Phases of clinical research
- Placebo-controlled study
- Potency
- Prediction
- Press release
- Quarter
- Replication
- Research
- Restructuring
- Reverse transcriptase
- Reverse-transcriptase inhibitor
- Risk
- Risk factor
- RNAI
- Securities Act of 1933
- Securities Exchange Act of 1934
- Shannon Ryan
- Small molecule
- Stock exchange
- Suffering
- Therapy
- Tolerability
- Trials
- U.S. Securities and Exchange Commission
- VBR
- Viral disease
- Viral replication
- Virology
- Webcast
- World Class